Sobi exercises opt-in right for Alprolix® - Seite 2

About Alprolix
Alprolix is a recombinant, clotting factor therapy developed for haemophilia B by fusing factor IX to the Fc portion of immunoglobulin G subclass 1, or IgG1 (a protein commonly found in the body). It is believed that this enables Alprolix to use a naturally occurring pathway to prolong the time the therapy remains in the body. While Fc fusion has been used for more than 15 years, Biogen and Sobi are the only companies to apply it in haemophilia.

About the Biogen and Sobi Collaboration
To exercise its opt-in right to take over final development and commercialization of Alprolix for its territory, Sobi will now make a payment into escrow of USD 10 million. Upon EU regulatory approval of Alprolix, Sobi will be liable to repay approximately half of the development and manufacturing costs for Alprolix incurred by Biogen, as well as for additional investments. Sobi estimates the total repayment obligation to reach approximately USD 201 million.

The cross-royalty and collaboration structure is described in detail in the Sobi press release dated 2012-02-06 "Sobi's agreement with Biogen Idec regarding long-lasting rFVIIIFc and rFIXFc hemophilia programs".

About Sobi
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of specialty and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion (USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com. 

For more information please contact

Media relations	Investor relations
Oskar Bosson, Head of Communications	Jörgen Winroth, Vice President, Head of Investor Relations
T: [phone]	T: [phone], [phone], [phone]
[e-mail]	[e-mail]